Trial reportBMJ (Clinical research ed.)1990
Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy.
Trial report in BMJ (Clinical research ed.), 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 131 citations in OpenAlex.
- Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study.The Clinical investigator · 1994Trial
- Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes.BMJ (Clinical research ed.) · 1993Trial
- Renal protective effect of enalapril in diabetic nephropathy.BMJ (Clinical research ed.) · 1992Trial
- A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.European journal of clinical pharmacology · 1992Trial
- Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.BMJ (Clinical research ed.) · 1991Trial
- Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group.BMJ (Clinical research ed.) · 1991Trial
- Elevated urine albumin creatinine ratio increases cardiovascular mortality in coronary artery disease patients with or without type 2 diabetes mellitus: a multicenter retrospective study.Cardiovascular diabetology · 2023Article
- Where does albuminuria come from in diabetic kidney disease?Current diabetes reports · 2008Review
- The changing epidemiology of diabetic microangiopathy in type 1 diabetes.Diabetologia · 2005Review
- Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction.Molecular and cellular biochemistry · 2003Article
- Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.Drugs · 1997Review
- Renoprotective role of ACE inhibitors in diabetic nephropathy.British heart journal · 1994Review
- Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function.British journal of clinical pharmacology · 1993Review
- Nephroprotective effect of ACE inhibitors.Drugs · 1993Review
- Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria.European journal of clinical pharmacology · 1993Article
- Review
- Renal protective effect of enalapril in diabetic nephropathy.BMJ (Clinical research ed.) · 1992Article
- Review
- Angiotensin converting enzyme inhibitors and diabetic nephropathy.BMJ (Clinical research ed.) · 1992Article
- New developments in renin and hypertension.BMJ (Clinical research ed.) · 1991Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether angiotensin converting enzyme inhibition reduces proteinuria in diabetic nephropathy more than blood pressure reduction with other antihypertensive treatment.
designProspective, open randomised study lasting eight weeks in patients with diabetic nephropathy.
settingOutpatient nephrology clinics. PATIENTS: 40 Patients with type I diabetes and diabetic nephropathy with reduced renal function.
interventionAntihypertensive treatment with enalapril or metoprolol, usually combined with frusemide.
main outcome measuresArterial blood pressure and urinary excretion of albumin and protein.
resultsArterial blood pressure after eight weeks was 135/82 (SD 13/7) mm Hg in the group given enalapril and 136/86 (16/12) mm Hg in the group given metoprolol. Proteinuria and albuminuria were similar in both groups before randomisation. After eight weeks' treatment, the geometric mean albumin excretion was 0.7 (95% confidence interval 0.5 to 1.2) g/24 h in the patients given enalapril and 1.6 (1.1 to 2.5) g/24 h in the patients given metoprolol (p less than 0.02). The proteinuria was 1.1 (0.7 to 1.7) and 2.4 (1.6 to 3.6) g/24 h respectively (p less than 0.02).
conclusionsAntihypertensive treatment with enalapril reduced proteinuria in patients with diabetic nephropathy more than an equally effective antihypertensive treatment with metoprolol. This points to a specific antiproteinuric effect of the angiotensin converting enzyme inhibitor independent of the effect on systemic blood pressure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.